NASDAQ: MURAMural Oncology PLC Stock
$3.58+0.05 (+1.42%)
Updated Apr 26, 2024
MURA Price
$3.58
Fair Value Price
N/A
Market Cap
$60.58M
52 Week Low
$3.23
52 Week High
$17.00
P/E
-0.29x
P/B
0.23x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$207.45M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$194M
Beta
1.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MURA Overview
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MURA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MURA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MURA is good value based on its book value relative to its share price (0.23x), compared to the US Biotechnology industry average (5.85x)
P/B vs Industry Valuation
MURA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MURA due diligence checks available for Premium users.
Be the first to know about important MURA news, forecast changes, insider trades & much more!
MURA News
Valuation
MURA fair value
Fair Value of MURA stock based on Discounted Cash Flow (DCF)
Price
$3.58
Fair Value
-$2.32
Undervalued by
254.09%
MURA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MURA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.29x
Industry
14.88x
Market
41.14x
MURA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.23x
Industry
5.85x
MURA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MURA's financial health
Profit margin
Revenue
$0.0
Net Income
-$59.5M
Profit Margin
0%
MURA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$301.7M
Liabilities
$37.9M
Debt to equity
0.14
MURA's short-term assets ($277.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MURA's short-term assets ($277.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MURA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$42.7M
Investing
-$1.2M
Financing
$315.0M
MURA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MURA vs Biotech Stocks
Mural Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.